Findings support the ongoing Phase 1 clinical development of BBI-940, an oral, selective kinesin degrader, as a potential first-in-class therapy for select advanced or metastatic breast cancers SAN ...
Expands the Company’s expertise in targeting pan-KRAS and other drivers of hard-to-treat cancers Acquisition adds a proprietary degrader antibody conjugate platform designed to overcome key ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results